Therefore, this study suggests that the HDAC3 inhibition could be a promising therapeutic strategy for HD patients and might be mediated by the reduction of MIF and the consequent possible downstream effects, including reduced astrocyte activation [60]. Here, MIF is linked to Huntington disease.